Merck and Co Inc (MRK): MRK reports 2Q23 results… PR: https:...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	827
Posts	119514
Boards Moderated	15
Alias Born	09/05/2002

DewDiligence

Re: DewDiligence post# 856

Tuesday, 08/01/2023 5:43:03 PM

Tuesday, August 01, 2023 5:43:03 PM

MRK reports 2Q23 results…

PR:
https://www.businesswire.com/news/home/20230801830764/en

Reuters:
https://finance.yahoo.com/news/1-merck-beats-quarterly-sales-104937970.html

Merck & Co raised its full-year revenue forecast on Tuesday as second-quarter sales of its top-selling products, cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil, sailed past Wall Street estimates.

Merck said Keytruda sales for the quarter jumped 19% to $6.3 billion, surpassing analysts' average estimate of $5.9 billion.

…Sales of Gardasil…surged 47% to $2.5 billion, also well above Wall Street estimates of $2.1 billion.

MRK sharply lowered 2023 non-GAAP EPS guidance due to a $10.2B charge ($4.02/sh) relating to in-process R&D from the acquisition of RXDX (#msg-171696785). The new guidance range is $2.95-3.05.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”